Novartis Resubmits Onbrez To FDA; Touts Comparative Trial Against Spiriva
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novartis AG, looking to position its once-daily Onbrez Breezhaler (indacaterol) to steal market share from the only once-daily bronchodilator approved for chronic obstructive pulmonary disease, Boehringer Ingelheim GMBH/Pfizer Inc.’s Spiriva (tiotropium), released Phase III data from a head-to-head study comparing the two products.
You may also be interested in...
COPD Market Snapshot: Firms Brush Off Near-term Generic Challenges, Focus On Pipelines
Generics are looming for top-selling chronic obstructive pulmonary disease therapies, but Big Pharma continues to see tremendous growth opportunities in the space
Despite European Nod, Novartis Gets FDA "Complete Response" For Indacaterol
FDA requests additional dosing information for the chronic obstructive pulmonary disorder drug, also known as QAB149.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.